Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)Uwe Platzbecker, Valeria Santini, Antonella Poloni et al.|Blood|2025Cited by 0
A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trialChiara Sartor, Antonio Curti, Anna Candoni et al.|Blood|2025Cited by 0